
Opinion|Videos|September 26, 2024
AGAVE-201: Axatilimab for cGVHD
Medical experts discuss the mechanism of action within axatilimab.
Advertisement
Video content above is prompted by the following:
- Axatilimab is pending FDA approval for cGVHD after failure of at least 2 prior lines of systemic therapy. Discuss its mechanism of action (MOA) and how this MOA might add value to cGVHD treatment landscape.
- Discuss phase 1/2 data (Kitko CL, et al. J Clin Oncol. 2022) and AGAVE-201 trial data with axatilimab for cGVHD (Wolff D, et al. ASH 2023).
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
3
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


